BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition

J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation / drug effects*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / pathology
  • Humans
  • Imidazoles / therapeutic use
  • MAP Kinase Kinase 1 / antagonists & inhibitors
  • MAP Kinase Kinase 1 / metabolism
  • MAP Kinase Kinase 2 / antagonists & inhibitors
  • MAP Kinase Kinase 2 / metabolism
  • Male
  • Middle Aged
  • Mutation*
  • Oximes / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / metabolism
  • Proto-Oncogene Proteins p21(ras)
  • Pyridones / therapeutic use
  • Pyrimidinones / therapeutic use
  • Treatment Outcome
  • ras Proteins / genetics*

Substances

  • Imidazoles
  • KRAS protein, human
  • Oximes
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Pyridones
  • Pyrimidinones
  • trametinib
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • dabrafenib